Healthlead Public Company (HL) Fair Value & Analysis
Healthcare · TH · Market cap 1.4B THB
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from 6.76 THB to 6.74 THB (−0.3%) since Jun 23, 2026. Share price −3.4% over the past month.
Price vs Fair Value (12 months)
12‑month range 5.50 THB – 7.84 THB · fair‑value band 5.05 THB – 8.42 THB · the 5.60 THB price screens below the 6.74 THB fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Healthlead Public Company (HL) currently trades at 5.60 THB, while our model-based Fair Value estimate is 6.74 THB — implying the stock looks roughly 20.4% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Healthlead Public Company generated revenue of 2.3B THB at a net margin of 3.3%. Revenue grew 2.8% year over year. It earns a return on equity of 7.7%. Net debt stands at 281M THB. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Healthlead Public Company Limited, together with its subsidiaries, engages in developing, importing, and distributing drugs, pharmaceuticals, cosmetic products, dietary supplements, medical devices, other healthcare products. It offers medicines, medical supplies and devices, as well as disinfectant and deodorizing products, masks, and sterilization products under the iCare, Pharmax, and Super Drug brands; and healthcare product innovations under PRIME, Besuto, and BOMSKIN brands. The company was incorporated in 2018 and is based in Nonthaburi, Thailand.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Healthlead Public Company reported revenue of 2.2B THB in FY2025 versus 1.2B THB in FY2021, a compound +16.8%/yr. Reported net income was 77.9M THB in FY2025, compounding −0.6%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc JDHIY | $4.26 | $6.93 | +63% |
| Alibaba Health Information Technology Limited ALBBY | $8.42 | $6.94 | -18% |
| Raia Drogasil S.A RADL3 | R$17.76 | R$14.97 | -16% |
| Yifeng Pharmacy Chain Co 603939 | ¥19.75 | ¥29.07 | +47% |
| Clicks Group CLCGY | $28.55 | $41.54 | +45% |
| Sugi Holdings SGIPF | $16.29 | $29.89 | +83% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Healthlead Public Company (HL) undervalued?
What is the fair value of HL?
What is the quality score of HL?
What is the revenue of Healthlead Public Company (HL)?
What is the net profit margin of HL?
Does Healthlead Public Company pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.